Mavyret

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:glecaprevir
gptkb:pibrentasvir
gptkbp:activities N S3/4 A protease inhibitor
N S5 A inhibitor
gptkbp:approves gptkb:FDA
gptkb:EMA
gptkbp:brand gptkb:Mavyret
gptkbp:class Antiviral
gptkbp:clinical_trial gptkb:ENDURANCE-1
gptkb:ENDURANCE-3
gptkb:SURVEYOR-1
gptkb:SURVEYOR-2
gptkb:SURVEYOR-3
Phase 3
gptkbp:contraindication Severe liver disease
gptkbp:dosage_form gptkb:tablet
gptkbp:duration 8 to 12 weeks
gptkbp:effective_date 2017-08-30
gptkbp:events Assessment for liver disease progression
HCVRNA testing
Regular monitoring of liver function
gptkbp:formulation Fixed-dose combination
https://www.w3.org/2000/01/rdf-schema#label Mavyret
gptkbp:indication gptkb:Chronic_Hepatitis_C
gptkbp:ingredients gptkb:Glecaprevir
gptkb:Pibrentasvir
gptkbp:interacts_with gptkb:Amiodarone
gptkb:St._John's_Wort
gptkb:Carbamazepine
gptkb:Rifampin
gptkbp:invention Patent protected
gptkbp:is_used_for Hepatitis C treatment
gptkbp:manager Oral
gptkbp:manufacturer gptkb:Abb_Vie
gptkbp:market Available
gptkbp:packaging Blister pack
gptkbp:population Adults
Pediatric patients over 12 years
gptkbp:previous_name gptkb:battle
gptkbp:price Varies by region
gptkbp:provides_information_on gptkb:AASLD
EASL
gptkbp:requires gptkb:theorem
gptkbp:safety_features Pregnancy category C
Not recommended during breastfeeding
Risk of liver injury
Risk of reactivation of Hepatitis B
gptkbp:side_effect gptkb:Nausea
Diarrhea
Fatigue
Headache
gptkbp:storage Store at room temperature
gptkbp:treatment Sustained virologic response
gptkbp:type_of_care Important for treatment success